Trial Profile
Efficacy and safety of lapatinib versus continued use of trastuzumab for trastuzumab-resistant human epidermal growth factor receptor 2 (HER2)-positive advanced breast cancer.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 11 Jan 2018
Price :
$35
*
At a glance
- Drugs Capecitabine (Primary) ; Lapatinib (Primary) ; Trastuzumab (Primary)
- Indications Breast cancer
- Focus Therapeutic Use
- 11 Jan 2018 New trial record
- 09 Dec 2017 Results (n=95) assessing efficacy, adverse effects and survival of lapatinib versus continued use of trastuzumab for trastuzumab-resistant human epidermal growth factor receptor 2 (HER2)-positive advanced breast cancer, were presented at the 40th Annual San Antonio Breast Cancer Symposium.